Myriad Genetics

MYGN

Market cap $563M

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).

MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until mid-to-late 2026.

Myriad Genetics (MYGN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.

Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.